Denali Therapeutics, Inc. (DNLI)
20.77
+1.23
(+6.29%)
USD |
NASDAQ |
Jun 09, 16:00
20.60
-0.17
(-0.82%)
After-Hours: 20:00
Denali Therapeutics SG&A Expense (Quarterly) : 33.51M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | 108.95M |
| ImmunityBio, Inc. | 45.77M |
| Summit Therapeutics, Inc. | 62.59M |
| Arrowhead Pharmaceuticals, Inc. | 41.74M |
| Biogen, Inc. | 607.30M |